Analyst Research

Report Title Price
Provider : Reuters Investment Profile
Provider : GlobalData
Provider : Wright Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

U.S. FDA accepts Veloxis Pharmaceuticals A/S' new drug application for envarsus

Thursday, 13 Mar 2014 01:44pm EDT 

Veloxis Pharmaceuticals A/S:Announced that the U.S. FDA accepted for standard review the company's New Drug Application (NDA) for Envarsus for the prevention of organ rejection in adult kidney transplant patients.Envarsus is Veloxis Pharmaceuticals A/S' once-daily tacrolimus based on the company's proprietary MELTDOSE technology.